Welcome to 2023, albeit we say it with caution, as the many annual soothsayers’ predictions – a selection of which we kick off with – are universally gloomy: beware horribly rising healthcare costs, potential recessions, a quiet capital/IPO market etc, etc.

However, the mighty dollar, some sanity on digital asset prices, high health insurer share prices, alongside continued predicted PMI/IPMI growth should bring some balance: see the 2022 performance of UnitedHealthcare, Cigna and Metlife.

And so, in turn, we might predict more global M&A in our space, as faster digitalisation/tech, scale, portfolio balance re-assert their importance for health insurers.

In most other areas there is very little of note to report, which I suppose is not that surprising for the very busy renewal month of December.